Delivery Order SPE2DB22D1041-SPE2DB25FUBQ3
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $3,808.18 to AmerisourceBergen Drug Corp for Synvisc-One Syringes (6mL), a hyaluronic acid-based injectable treatment for osteoarthritis. This firm fixed-price, competitively awarded delivery order was issued on September 18, 2025, with an ultimate completion date of September 19, 2025, and will be performed at the awardee's corporate office in Conshohocken, Pennsylvania. The contract carries no set-aside designation, indicating...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Synvisc-One Syringe 6mL, a hyaluronic acid-based joint injection used for osteoarthritis treatment. This competitively awarded, non-set-aside contract was finalized on August 18, 2025, with a ceiling value of $4,087.80 and a firm fixed price structure. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania, with an ultimate completion date of August 19, 2025. This...
- AmerisourceBergen Drug Corp was awarded a delivery order by the Defense Logistics Agency valued at $10,419.84 for Synvisc-One Syringe 6ML, a hyaluronic acid-based joint injection used to treat osteoarthritis pain. The contract, awarded on June 2, 2025, with an ultimate completion date of June 3, 2025, is a firm fixed price delivery order with no set-aside designation. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This award represents a...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 25, 2025, for the supply of Synvisc-One Syringe 6ML, a hyaluronic acid injection used for osteoarthritis treatment. Valued at $7,796.10 with a firm fixed price structure, this non-set-aside delivery order is scheduled for completion by August 26, 2025, and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. This award represents a child delivery order under...
- The Defense Logistics Agency awarded a $25.2K delivery order to AmerisourceBergen Drug Corp on September 17, 2025, for the supply of Synvisc-One Syringe 6ML, a hyaluronic acid-based joint injection used for osteoarthritis treatment. This firm fixed-price, non-set-aside contract is scheduled for completion by September 18, 2025, with performance at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The award represents a routine pharmaceutical procurement under the company's existing...
- The Defense Logistics Agency awarded a delivery order valued at $1,605.68 to AmerisourceBergen Drug Corp for SYNVISC-One Syringe 6ml, a hyaluronic acid-based joint injection used to treat osteoarthritis symptoms. The contract, issued on September 9, 2025, with a completion date of September 10, 2025, represents a firm fixed price delivery order with no set-aside designation, indicating it was competitively awarded. AmerisourceBergen, a major pharmaceutical distributor headquartered in...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 21, 2025, for the supply of Synvisc-One Syringe 6ML, a hyaluronic acid injection used for knee osteoarthritis treatment. This non-set-aside, competitively awarded contract carries a ceiling value of $11,322.76 under a firm fixed price arrangement, with an ultimate completion date of August 22, 2025. The delivery will be performed at AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order valued at $13,608.77 to AmerisourceBergen Drug Corp for the supply of Synvisc-One Syringe 6ML, a hyaluronic acid-based injection used for knee osteoarthritis treatment. This firm fixed-price delivery order, issued on August 19, 2025, with an ultimate completion date of August 20, 2025, represents a direct procurement through AmerisourceBergen's existing indefinite delivery contract vehicle with DLA. The award carried no set-aside designation,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Synvisc-One Syringe 6ML, a hyaluronic acid injection used for knee osteoarthritis treatment. This firm fixed-price delivery order, valued at $3,246.60, was awarded on August 25, 2025, with an ultimate completion date of August 26, 2025. The contract represents a non-competitive delivery order issued under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support...
- The Defense Logistics Agency awarded a $1,729.05 delivery order to AmerisourceBergen Drug Corp for Synvisc-One Syringe 6ML, a pharmaceutical product used in joint pain management. This firm fixed price contract, issued on July 29, 2025, represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The delivery order specifies a place of performance in...
- SPE2DB22D1041Indefinite Delivery Contract
- SPE2DB22D1041-SPE2DB25FUBQ3Delivery Order
The Defense Logistics Agency awarded a $8,624.13 delivery order to AmerisourceBergen Drug Corp for Synvisc-One Syringe 6ML, a hyaluronic acid-based intra-articular injection used for osteoarthritis pain management. Issued on September 2, 2025, with completion targeted for September 3, 2025, this firm fixed price delivery order was competitively awarded without set-aside designation. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company maintains its corporate headquarters. This delivery order is issued under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The IDC serves as a comprehensive pharmaceutical supply vehicle supporting military healthcare systems globally, enabling the delivery of brand-name and generic medications, specialty drugs, vaccines, and medical supplies across multiple therapeutic domains. AmerisourceBergen's role as a prime pharmaceutical vendor for the DLA reflects its critical position in the federal medical supply chain, serving the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $8.6k | 9/2/25 |